

-continued

```

<210> SEQ ID NO 3
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Botulinum neurotoxin type A
<220> FEATURE:

```

```

<400> SEQUENCE: 3

```

```

Gly Ile Thr Asn Lys Cys Lys Met Asn Leu
          5                      10

```

```

Gln Asp Asn Asn Gly Asn Asp Ile Gly Phe
          15                      20

```

```

Ile Gly Phe His Gln
          25

```

```

<210> SEQ ID NO 4
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Botulinum neurotoxin type A
<220> FEATURE:

```

```

<400> SEQUENCE: 4

```

```

Ala Leu Asn Asp Leu Cys Ile Lys Val Asn
          5                      10

```

```

Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu
          15                      20

```

```

Asp Asn Phe Thr Asn
          25

```

What is claimed is:

1. A monoclonal antibody, MAb 4A2-2, produced from hybridoma cell line ATCC PTA-971.

2. A monoclonal antibody, MAb 6B2-2, produced from hybridoma cell line ATCC PTA-969.

3. A monoclonal antibody, MAb 6C2-4, produced from hybridoma cell line ATCC PTA-970.

4. A continuous hybridoma cell line having deposit accession number ATCC PTA-971, and clones thereof, which cell line produces monoclonal antibody to BoNT/A.

5. A continuous hybridoma cell line having deposit accession number ATCC PTA-969, and clones thereof, which cell line produces monoclonal antibody to BoNT/A.

6. A continuous hybridoma cell line having deposit accession number ATCC PTA-970, and clones thereof, which cell line produces monoclonal antibody to BoNT/A.

7. A monoclonal antibody which binds an epitope comprising amino acids 1150-1289 of BoNT/A.

8. A monoclonal antibody which binds an epitope comprising amino acids 1157-1181 of BoNT/A.

9. A monoclonal antibody which binds an epitope comprising amino acids 1230-1253 of BoNT/A.

10. A monoclonal antibody which binds an epitope comprising 1157-1253 of BoNT/A.

11. A DNA sequence encoding an antigen binding domain of the monoclonal antibody of claim 1, and any portion thereof still capable of binding to said antigen.

12. A DNA sequence encoding an antigen binding domain of the monoclonal antibody of claim 2, and any portion thereof still capable of binding to said antigen.

13. A DNA sequence encoding an antigen binding domain of the monoclonal antibody of claim 3, and any portion thereof still capable of binding to said antigen.

14. A method for detecting BoNT/A said method comprising:

(i) incubating a sample with an effective amount of at least one monoclonal antibody against BoNT/A, under conditions which allow the formation of an antibody-BoNT/A complex; and

(ii) detecting the antibody-BoNT/A complex wherein the presence or absence of the complex indicates the presence or absence of BoNT/A in the sample.

15. A method for detecting BoNT/A according to claim 14 wherein, said monoclonal antibody is chosen from the group consisting of 4A2-2, 6B2-2, and 6C2-4.

16. A method for detecting BoNT/A according to claim 15 wherein, said sample is water, biologicals, pharmaceuticals, or food products.

17. A method of treating BoNT/A intoxication comprising administering to a patient in need of said treatment an amount of a monoclonal antibody selected from the group consisting of: 4A2-2, 6B2-2, and 6C2-2 sufficient to effect said treatment.

18. A pharmaceutical composition comprising the monoclonal antibody of claim 1 in a concentration sufficient to inhibit botulism poisoning, together with a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising the monoclonal antibody of claim 2 in a concentration sufficient to inhibit botulism poisoning, together with a pharmaceutically acceptable carrier.